
ESOCAP WAS FEATURED IN *GOINGPUBLIC* MAGAZINE

Basel, Switzerland, April 12, 2023

EsoCap AG has been selected to be featured in GoingPublic Magazine, a major German magazine for corporate finance and investment topics.

"We are very pleased to be featured in GoingPublic Magazine as a company that is at the forefront of providing drug discovery and development solutions and transforming businesses," said Isabelle Racamier, CEO of EsoCap AG, "This recognition reinforces our determination to make a difference in patients' lives through EsoCap's promising and innovative technology."

About GoingPublic Magazine

Founded in 1998, GoingPublic Media AG (www.goingpublic.ag) is one of the leading media companies for corporate finance and investment topics. As part of its cross-media platform approach, the Group publishes around 40 magazine issues a year and operates three web platforms in conjunction with online newsletters and social media presences. In addition, the media company organizes around 15 events each year.

About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with severe upper gastrointestinal tract diseases by developing a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve with the current standard of care because the contact time of the drug from the mouth to the stomach is extremely short at one to two seconds.

EsoCap has a unique drug delivery platform that enables local treatment of upper gastrointestinal tract disorders with an unprecedented prolonged contact time with the esophageal mucosa.

For more information, please visit www.esocapbiotech.com and follow EsoCap on [LinkedIn](#) and [Twitter](#).

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com

